Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:GLMDNASDAQ:PHXMNASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.30+2.3%$7.91$6.51▼$13.27$8.80M1.6294,012 shs2,636 shsGLMDGalmed Pharmaceuticals$1.72+7.2%$1.41$1.15▼$23.80$2.84M0.511.38 million shs776,508 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ATLPHTalphera$0.48-1.8%$0.50$0.45▼$1.19$9.86M-0.1154,567 shs36,118 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics0.00%-19.41%+2.60%+10.51%-4.25%GLMDGalmed Pharmaceuticals0.00%+5.96%+34.45%-36.00%-59.92%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%TLPHTalphera0.00%-1.96%-0.79%-12.28%-52.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.6837 of 5 stars3.55.00.00.02.70.80.0GLMDGalmed Pharmaceuticals1.081 of 5 stars0.02.00.00.03.32.50.6PHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATLPHTalphera2.4443 of 5 stars3.83.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00261.45% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ATLPHTalphera 3.50Strong Buy$5.00939.50% UpsideCurrent Analyst Ratings BreakdownLatest GLMD, PHXM, TLPH, and ADXN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025TLPHTalpheraHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K21.77N/AN/A$1.20 per share6.92GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$33.02 per shareN/APHXMPHAXIAM Therapeutics$32.66M0.32N/AN/A$7.98 per share0.39TLPHTalphera$27K365.26N/AN/A$0.83 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%9/1/2025 (Estimated)GLMDGalmed Pharmaceuticals-$6.91M-$16.66N/A∞N/AN/A-28.75%-24.98%8/26/2025 (Estimated)PHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ATLPHTalphera-$18.40M-$0.45N/AN/AN/AN/A-118.46%-65.82%8/12/2025 (Estimated)Latest GLMD, PHXM, TLPH, and ADXN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A3/31/2025Q4 2024TLPHTalphera-$0.21-$0.07+$0.14-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59GLMDGalmed PharmaceuticalsN/A7.037.03PHXMPHAXIAM Therapeutics0.231.78N/ATLPHTalpheraN/A4.424.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%GLMDGalmed Pharmaceuticals76.14%PHXMPHAXIAM Therapeutics0.40%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%GLMDGalmed Pharmaceuticals19.80%PHXMPHAXIAM Therapeutics1.94%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableGLMDGalmed Pharmaceuticals201.65 million516,000Not OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataTLPHTalphera1920.50 million16.48 millionOptionableGLMD, PHXM, TLPH, and ADXN HeadlinesRecent News About These Companiestalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comTalphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financingMay 15, 2025 | msn.comTalphera, Inc. (TLPH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025May 7, 2025 | prnewswire.comAll You Need to Know About Talphera (TLPH) Rating Upgrade to Strong BuyMay 7, 2025 | msn.comTalphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?April 5, 2025 | msn.comTalphera reports Q4 EPS (7c) vs. (25c) last yearApril 1, 2025 | markets.businessinsider.comTalphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comTalphera announces agreement with FDA to reduce NEPHRO CRRT study sizeApril 1, 2025 | markets.businessinsider.comTalphera Reports 2024 Financial Results and Study UpdateMarch 31, 2025 | tipranks.comTalphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of NiyadMarch 31, 2025 | msn.comTalphera, Inc. (TLPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionMarch 31, 2025 | prnewswire.com7TLPH : Earnings Outlook For TalpheraMarch 28, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLMD, PHXM, TLPH, and ADXN Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.30 +0.19 (+2.34%) As of 02:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Galmed Pharmaceuticals NASDAQ:GLMD$1.72 +0.12 (+7.19%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 06/13/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Talphera NASDAQ:TLPH$0.48 -0.01 (-1.84%) As of 03:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
